Related Experiment Video

Updated: Jun 21, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

Reduced Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once Daily Intravenous Busulfan for

Carl Shultz1, Shreyas Shirodkar2, Chelby Wakefield1

  • 1Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV.

Transplantation and Cellular Therapy
|June 19, 2026
PubMed
Summary

No abstract available in PubMed .

Keywords:
Busulfan Conditioning Stem Cell Transplant Refractory Lymphoma

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Jun 21, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Articles linked to this work by shared authors, journal, and citation graph.

Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma.

Transplantation and cellular therapy·2026

Sweet cherry pomace polyphenols disrupt Salmonella enteritidis colonization on chicken skin.

Food microbiology·2026

Growth performance and body composition of Eimeria-infected broiler fed berry pomaces and a Limosilactobacillus reuteri isolate.

Poultry science·2025

Evaluation of Titer-Proven Response Rates of Pediatric Hepatitis B-Combination Vaccines in Adult Hematopoietic Cell Transplant Recipients.

Transplant infectious disease : an official journal of the Transplantation Society·2025

Investigation of an Outbreak of Equine Herpesvirus-1 Myeloencephalopathy in a Population of Aged Working Equids.

Viruses·2025

Medication-Induced Lymphomatoid Granulomatosis Presenting as a Solitary Periocular Cutaneous Lesion.

Ophthalmic plastic and reconstructive surgery·2024

A Comprehensive Rehabilitation Framework to help optimize outcomes across the CAR-T Continuum - White Paper Report.

Transplantation and cellular therapy·2026

Challenges with expansion of cell and gene therapy: A call for system-level action.

Transplantation and cellular therapy·2026

A Bayesian Survival Model to Support the Selection of the Best Hematopoietic Stem Cell Donor.

Transplantation and cellular therapy·2026

Phenotype-Specific Associations Between Graft‑Versus‑Host Disease and Post‑Transplant Outcomes.

Transplantation and cellular therapy·2026

Insights to provider practice of germline testing for inherited hematologic malignancy predisposition syndromes to inform hematopoietic stem cell transplantation.

Transplantation and cellular therapy·2026

Reduced Cumulative Post-Transplant Cyclophosphamide Exposure Is Associated with Increased Acute and Chronic Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026

Type-II-CD20-targeted therapy for CD38 antibody-refractory antibody-mediated rejection after kidney transplantation: a case report.

Frontiers in immunology·2026

Donor-derived cell-free DNA testing for noninvasive monitoring of allograft rejection after lung transplantation.

Frontiers in immunology·2026

Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation.

Pediatric transplantation·2026

CD4- and CD8-to-Total Lymphocyte Ratios to Guide Rabbit Anti-Thymocyte Globulin Induction in Kidney Transplant Recipients: A Single-Center Feasibility Study.

Nephrology (Carlton, Vic.)·2026

Integrating Deceased and Living Donation: Six-Year Outcomes of the Italian Deceased-Donor-Initiated Kidney Paired Exchange (DEC-K) Program.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026

Posttransplant lymphoproliferative disorder in vascularized composite allotransplantation: a systematic review with institutional cases.

Clinical transplantation and research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us